HIV infection in women: Do sex and gender matter?
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
At least half of all HIV infections occur in women. Most women are of childbearing potential; therefore, issues encompassing reproduction and mother-to-child transmission are critical in the management of this population. The efficacy of antiretroviral therapy (ART) is similar in men and women, although rates of adverse events or toxicity may be higher in women, which, in turn, may be related to higher antiretroviral drug levels documented in pharmacokinetic studies. A substantial proportion of women may not derive the benefit of highly active ART because nonsuppressive regimens are commonly used, especially in resource-limited settings, to decrease mother-to-child transmission. The likely emergence of resistant virus can have long-term sequelae for the mother, child, and other exposed individuals. Additional studies are needed of sex/gender-related issues including antiretroviral toxicities, pharmacokinetic profiles of approved and novel agents, ART strategies during pregnancy to minimize HIV resistance, and determination of optimal antiretroviral regimens for women.
- UNAIDS/WHO: AIDS epidemic update: November 19, 2007. Available at http://www.unaids.org/en/knowledgecenter/HIVdata/epiupdate. Accessed February 13, 2008.
- Centers for Disease Control and Prevention (CDC): HIV transmission among black women—North Carolina, 2004. MMWR Morb Mortal Wkly Rep 2005, 54:89–94.
- Joint United Nations Program on HIV/AIDS (UNAIDS): Report on the global AIDS epidemic. Available at http://www.unaids.org/en/knowledgecenter/HIVdata/GlobalReport/2006. Accessed September 22, 2007.
- De Cock KM, Mbori-Ngacha D, Marum E: Shadow on the continent: public health and HIV/AIDS in Africa in the 21st century. Lancet 2002, 360:67–72. CrossRef
- Centers for Disease Control and Prevention: HIV/AIDS statistics and surveillance. Available at http://www.cdc.gov/topics/surveillance. Accessed October 6, 2007.
- Gray GE, McIntyre JA: Effect of HIV on women. AIDS Read 2006, 16:365–368, 373–377.
- Ramjee G, Williams B, Gouws E, et al.: The impact of incident and prevalent herpes simplex virus-2 infection on the incidence of HIV-1 infection among commercial sex workers in South Africa. J Acquir Immune Defic Syndr 2005, 39:333–339. CrossRef
- Quinn TC, Wawer MJ, Sewankambo N, et al.: Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000, 342:921–929. CrossRef
- Watson-Jones D, Weiss HA, Rusizoka M, et al.: HSV trial team; Steering and Data Monitoring Committees: Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med, 2008, 358:1560–1571. CrossRef
- Zorrilla CD: Antiretroviral combination therapy in HIV-1 infected women and men: are their responses different? Int J Fertil Womens Med 2000, 45:195–199.
- Dunkle KL, Jewkes RK, Brown HC, et al.: Gender-based violence, relationship power, and risk of HIV infection in women attending antenatal clinics in South Africa. Lancet 2004, 363:1415–1421. CrossRef
- Clark RA, Squires KE: Gender-specific considerations in the antiretroviral management of HIV-infected women. Expert Rev Anti Infect Ther, 2005, 3:213–227. CrossRef
- Gardner LI, Holmberg SD, Moore J, et al.: Use of highly active antiretroviral therapy in HIV-infected women: impact of HIV specialist care. J Acquir Immune Defic Syndr 2002, 29:69–75.
- Gandhi M, Bacchetti P, Miotti P, et al.: Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis 2002, 35:313–322. CrossRef
- Sterling TR, Vlahov D, Astemborski J, et al.: Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001, 344:720–725. CrossRef
- Junghans C, Ledergerber B, Chan P, et al.: Sex differences in HIV-1 viral load and progression to AIDS. Swiss HIV Cohort Study. Lancet 1999, 353:589; author reply 590–591. CrossRef
- Moroni M: Sex differences in HIV-1 viral load and progression to AIDS. ICONA Study Group. Italian cohort of HIV-1 positive individuals. Lancet 1999, 353:589–590; author reply 590–591. CrossRef
- Evans JS, Nims T, Cooley J, et al.: Serum levels of virus burden in early-stage human immunodeficiency virus type 1 disease in women. J Infect Dis 1997, 175:795–800. CrossRef
- Sterling TR, Lyles CM, Vlahov D, et al.: Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. J Infect Dis 1999, 180:666–672. CrossRef
- Moore RD, Cheever L, Keruly JC, Chaisson RE: Lack of sex difference in CD4 to HIV-1 RNA viral load ratio. Lancet 1999, 353:463–464. CrossRef
- Anastos K, Gange SJ, Lau B, et al.: Association of race and gender with HIV-1 RNA levels and immunologic progression. J Acquir Immune Defic Syndr 2000, 24:218–226.
- Prins M, Robertson JR, Brettle RP, et al.: Do gender differences in CD4 cell counts matter? AIDS 1999, 13:2361–2364. CrossRef
- Hader SL, Smith DK, Moore JS, Holmberg SD: HIV infection in women in the United States: status at the millennium. JAMA 2001, 285:1186–1192. CrossRef
- Moore AL, Kirk O, Johnson AM, et al.: EuroSIDA group: Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr 2003, 32:452–461. CrossRef
- Benson CA, Collier AC, Bosch R, et al.: Pre-treatment factors that predict responses to potent antiretroviral therapy: findings from the AACTG A5001. Presented at 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA: February 10–14, 2003.
- Palella FJ, Gathe J, Brutus A, et al.: Gender comparisons in long term responses among patients receiving nelfinavir and dual nucleoside reverse transcriptase inhibitors as first ever highly active antiretroviral activity. Presented at XIV International AIDS Conference. Barcelona, Spain: July 7–12, 2002. Abstract WePeB5967.
- Keiser P, Yazdani B, Koen G et al.: The effect of gender and weight on treatment outcome in nelfinavir-treated patients: a case control study. Presented at 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA: February 10–14, 2003.
- Gandhi, M, Aweeka F, Greenblatt RM, Blaschke TF: Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 2004, 44:499–523. CrossRef
- Fletcher CV, Jiang H, Brundage RC, et al.: Sex differences in virologic response and saquinavir pharmacology in ACTG 359. Antiviral Ther 2003, 8(Suppl 1): abstr 128.
- Wathen L, Freimuth W, Cox S, et al.: Combination therapy with delavirdine plus zidovudine versus zidovudine alone: demographics, HIV viral load and CD4 changes in female patients. Presented at the 1997 National Conference on Women and HIV. Pasadena, CA: May 4–7, 1997.
- Moore RD, Keruly JC, Chaisson RE: Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. AIDS 2001, 15:617–620. CrossRef
- Bersoff-Matcha SJ, Miller WC, Aberg JA, et al.: Sex differences in nevirapine rash. Clin Infect Dis 2001, 32:124–129. CrossRef
- Currier JS, Yetzer E, Potthoff A, et al.: Gender differences in adverse events on ritonavir: an analysis from the Abbot 247 study. Presented at the 1997 National Conference on Women and HIV. Pasadena, CA: May 4–7, 1997. Abstract 304.7.
- Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM): Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr 2006, 42:562–571. CrossRef
- Tien PC, Cole SR, Williams CM, et al.: Incidence of lipoatrophy and lipohypertrophy in the women’s interagency HIV study. J Acquir Immune Defic Syndr 2003, 34:461–466. CrossRef
- Gervasoni C, Ridolfo AL, Trifirò G, et al.: Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999, 13:465–471. CrossRef
- Justman JE, Benning L, Danoff A, et al.: Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003, 32:298–302. CrossRef
- Howard AA, Floris-Moore M, Arnsten JH, et al.: Disorders of glucose metabolism among HIV-infected women. Clin Infect Dis 2005, 40:1492–1499. CrossRef
- Dolan SE, Huang JS, Killilea KM, et al.: Reduced bone density in HIV-infected women. AIDS 2004, 18:475–483. CrossRef
- Arnsten JH, Freeman R, Santorol N et al.: HIV infection and protease inhibitor use are not associated with reduced bone mineral density in older HIV-infected women. Presented at 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA: February 10–14, 2003.
- Anastos K, Hessol N: The association of bone mineral density with HIV infection and antiretroviral treatment in women. Presented at 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA: February 8–11, 2004.
- Clark RA, Theall K: Population-based study evaluating association between selected antiretroviral therapies and potential oral contraceptive failure. J Acquir Immune Defic Syndr 2004, 37:1219–1220. CrossRef
- Currier J: HIV Infection in women: an update. HIV/AIDS Annual Update 2003. Available at http://www.clinicaloptions.com/HIV.aspx (learning modules). Accessed October 10, 2007.
- Mildvan D, Yarrish R, Marshak A, et al.: Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. J Acquir Immune Defic Syndr 2002, 29:471–477.
- Watts D, Minkoff H: Managing pregnant patients. In AIDS Therapy. Edited by Dolin R, Masur H, Saag MS. Philadelphia: Elsevier; 2003:381–399.
- Loko MA, Toure S, Dakoury-Dogbo N, et al.: Decreasing incidence of pregnancy by decreasing CD4 cell count in HIV-infected women in Cote d’Ivoire: a 7-year cohort study. AIDS 2005, 19:443–445. CrossRef
- Bucceri A, Luchini L, Rancilio L, et al.: Pregnancy outcome among HIV positive and negative intravenous drug users. Eur J Obstet Gynecol Reprod Biol 1997, 72:169–174. CrossRef
- Mofenson LM; Centers for Disease Control and Prevention, US Public Health Service Task Force: US Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. MMWR Recomm Rep 2002, 51(RR-18):1–38; quiz CE1–4.
- Watts DH: Management of human immunodeficiency virus infection in pregnancy. N Engl J Med 2002, 346:1879–1891. CrossRef
- Connor EM, Sperling RS, Gelber R, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994, 331:1173–1180. CrossRef
- De Santis M, Carducci B, De Santis L, et al.: Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med 2002, 162:355. CrossRef
- Fundarò C, Genovese O, Rendeli C, et al.: Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 2002, 16:299–300. CrossRef
- Bryson Y, Stek A, Mirochnick M, et al.: for the PACTG 353 Team: Pharmacokinetics (PK), antiviral activity and safety of nelfinavir (NFV) with ZDV/3TC in pregnant HIV-infected women and their infants: PACTG 353 Cohort 2. Presented at 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA: February 24–28, 2002.
- Acosta EP, Bardeguez A, Zorrilla CD, et al.: Prediatric AIDS Clinical Trials Group 386 Protocol Team: Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004, 48:430–436. CrossRef
- Stek A, Mirochnick M, Capparelli E et al.: Reduced lopinavir exposure during pregnancy: preliminary pharmacokinetic results from PACTG 1026. Presented at XV International AIDS Conference. Bangkok, Thailand: July 11–16, 2004.
- Mirochnick M, Fenton T, Gagnier P, et al.: Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998, 178:368–374.
- Taha TE, Kumwenda NI, Hoover DR, et al.: Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA 2004, 292:202–209. CrossRef
- Thistle P, Spitzer RF, Glazier RH, et al.: A randomized, double-blind, placebo-controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe. Clin Infect Dis 2007, 44:111–119. CrossRef
- Lallemant M, Jourdain G, Le Coeur S, et al.: Perinatal HIV Prevention Trial (Thailand) Investigators: Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004, 351:217–228. CrossRef
- Nolan M, Fowler MG, Mofenson LM: Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance. J Acquir Immune Defic Syndr 2002, 30:216–229.
- Eshleman SH, Becker-Pergola G, Deseyve M, et al.: Impact of human immunodeficiency virus type 1 (HIV-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent HIV-1 vertical transmission (HIV network for prevention trials 012 study). J Infect Dis 2001, 184:914–917. CrossRef
- Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al.: Agence Nationale de Recherches sur le SIDA (ANRS) 075 Study Group: Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001, 285:2083–2093. CrossRef
- Flys TS, Donnell D, Mwatha A, et al.: Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis 2007, 195:711–715. CrossRef
- McConnell M, Bakaki P, Eure C, et al.: Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda. J Acquir Immune Defic Syndr 2007, 46:291–296. CrossRef
- Jourdain G, Ngo-Giang-Huong N, Tungyai P, et al.: Perinatal HIV Prevention Trial Group: Exposure to intrapartum single-dose nevirapine and subsequent maternal six month response to NNRT1 regimens. Presented at 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA: February 8–11, 2004.
- HIV infection in women: Do sex and gender matter?
Current Infectious Disease Reports
Volume 10, Issue 5 , pp 423-431
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links